Proteome Analyses Reveal S100A11, S100P, and RBM25 Are Tumor Biomarkers in Colorectal Cancer.

PURPOSE: The prognosis for colorectal cancer (CRC) patients is drastically impacted by the presence of lymph node or liver metastases at diagnosis or resection. On this basis it is sought to identify novel proteins as biomarkers and determinants of CRC metastasis. EXPERIMENTAL DESIGN: Proteomic analyses are undertaken using primary tissues from ten Chinese CRC patients presenting with or without liver metastases and immunohistochemistry used to validate selected proteins in an independent patient cohort. RESULTS: Comparing CRC against paired normal adjacent tissues identifies 1559 differentially expressed proteins (DEPs) with 974 upregulated and 585 downregulated proteins, respectively. The highest number of DEPs is selectively associated with metastatic tumors (519 upregulated and 267 downregulated proteins, respectively) with a smaller number of unique DEPs identified only in non-metastatic CRC cases (116 upregulated and 29 downregulated proteins, respectively). The remaining DEPs are commonly expressed in both non-metastatic and metastatic tumors. The upregulation of three representative DEPs (S100A11, S100P, and RBM25) is confirmed using immunohistochemistry against 154 CRC tissues embedded in a tissue microarray. CONCLUSIONS AND CLINICAL RELEVANCE: The data reveal both previously identified CRC biomarkers along with novel candidates which provide a ready resource of DEPs in CRC for further investigation.

[Study of adiponectin expression in placenta and its correlation with preeclampsia].

OBJECTIVE: To investigate the expression of adiponectin in placenta and its correlation with preeclampsia. METHODS: Placental tissues were collected from normal term pregnancies (normal pregnancy group, n = 20), mild preeclampsia (mild preeclampsia group, n = 12) and severe preeclampsia (severe preeclampsia group, n = 22). The expression of adiponectin protein and the intensity of its mRNA in placenta were detected using immunohistochemistry and RT-PCR, respectively. Integral optical density (IOD) which represents the expression level of adiponectin protein, and the ratio of adiponectin cDNA PCR products to beta-actin cDNA PCR products which represents the intensity of transcription of adiponectin mRNA in placenta were analyzed. RESULTS: (1) The expression of adiponectin protein was observed in cytoplasm of placental cytotrophoblasts and syncytiotrophoblasts among three groups. There was no significant difference in adiponectin protein expression between maternal side and fetal side of placenta in three groups (all P > 0.05); (2) The expression of adiponectin protein in placenta in severe preeclampsia group (30 984 +/- 14 604) was significantly lower than that of mild preeclampsia group (58 360 +/- 8910, P < 0.01) and of normal pregnancy group (53 246 +/- 17 554, P < 0.01). There was also no significant difference in the expression of adiponectin protein in placenta between term delivery and preterm delivery in severe preeclampsia group (38 890 +/- 20 386 vs 29 319 +/- 8997, P > 0.05), however, the expression of adiponectin protein in placenta in term delivery of severe preeclampsia group was significantly lower than that of term delivery of normal pregnancy group (38 890 +/- 20 386 vs 53 246 +/- 17 554, P < 0.05); (3) The expression of adiponectin mRNA was detected in placental tissues among three groups also. The intensity of transcription of adiponectin in placenta in severe preeclampsia group (1.0 +/- 0.2) was markedly lower than that of mild preeclampsia group (2.9 +/- 0. 8, P < 0.05) and normal pregnancy group (3.3 +/- 1.1, P = 0.000). CONCLUSION: The expression of adiponectin decreases in placenta tissues of severe preeclampsia, indicating that the abnormal expression of adiponectin may be involved in the pathogenesis of preeclampsia.